Jazz Pharmaceuticals JAZZ Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $682.7M-71.7% | $2.41B+60.2% | $1.51B+70.9% | $881.48M+49.0% | ||
| $830.7M+15.9% | $716.77M+1.6% | $705.79M+8.3% | $651.49M+15.6% | ||
| $417M-13.2% | $480.45M-19.5% | $597.04M-16.4% | $714.06M-33.4% | ||
| $4.17B-10.0% | $4.63B+34.7% | $3.44B+31.8% | $2.61B-0.2% | ||
| $199.9M+15.3% | $173.41M+2.2% | $169.65M-25.6% | $228.05M-11.2% | ||
| $1.83B+6.6% | $1.72B-2.1% | $1.75B+3.6% | $1.69B-7.4% | ||
| $4.43B-6.9% | $4.76B-12.2% | $5.42B-6.5% | $5.79B-19.0% | ||
| $1.05B+81.0% | $580M+383% | $120M— | $0— | ||
| $11.66B-2.9% | $12.01B+5.4% | $11.39B+5.2% | $10.84B-11.9% | ||
| $122.1M+56.8% | $77.87M-24.2% | $102.75M+13.2% | $90.76M-9.5% | ||
| $1.03B+3,222% | $31M-94.9% | $604.95M+1,851% | $31M0.0% | ||
| $2.24B+116% | $1.04B-32.4% | $1.54B+64.7% | $933.19M+15.3% | ||
| $4.33B-28.8% | $6.08B+19.0% | $5.11B-10.3% | $5.69B-5.4% | ||
| $0-100% | $6K0.0% | $6K0.0% | $6K0.0% | ||
| $646.1M-42.7% | $1.13B+28.3% | $878.66M+19.8% | $733.59M-11.6% | ||
| $4.32B+5.5% | $4.09B+9.5% | $3.74B+21.1% | $3.09B-22.2% | ||
| $11.66B-2.9% | $12.01B+5.4% | $11.39B+5.2% | $10.84B-11.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Jazz Pharmaceuticals's total assets?
- Jazz Pharmaceuticals (JAZZ) holds $11.9B in total assets, up 2.8% year over year.
- How much debt does Jazz Pharmaceuticals have?
- Jazz Pharmaceuticals carries $5.4B in total debt against $4.5B of shareholders' equity, a debt-to-equity ratio of 1.19.
- How much cash does Jazz Pharmaceuticals have?
- Jazz Pharmaceuticals holds $667.5M in cash and equivalents.
- Can Jazz Pharmaceuticals cover its short-term obligations?
- Its current ratio is 2.04 — current assets exceed current liabilities.
- Where does Jazz Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Jazz Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
